Literature DB >> 25394672

Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies.

Masaomi Tomonaga1, Noriho Sakamoto, Yuji Ishimatsu, Tomoyuki Kakugawa, Tatsuhiko Harada, Shota Nakashima, Atsuko Hara, Shintaro Hara, Yoshihiro Horai, Atsushi Kawakami, Hiroshi Mukae, Shigeru Kohno.   

Abstract

Anti-PL-7 is an anti-tRNA synthetase antibody, and interstitial lung disease (ILD) is the most frequent complication of anti-PL-7-associated antisynthetase syndrome. However, the features of ILD have not been fully elucidated. The present study retrospectively compares 7 and 15 patients who were positive for anti-PL-7 and anti-Jo-1 antibodies, respectively. The features of ILD did not significantly differ between the two groups, but the ratio of lymphocytes in bronchoalveolar lavage fluid was higher in the Jo-1 than in the PL-7 group. High-resolution computed tomography revealed nonspecific interstitial pneumonia in all patients in the PL-7 group and organizing pneumonia in four of the 15 patients in the Jo-1 group. These findings suggest that pulmonary complications slightly differ between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Further studies are required to clarify the features of ILD associated with PL-7.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394672     DOI: 10.1007/s00408-014-9665-7

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  18 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen
Journal:  Autoimmun Rev       Date:  2012-02-03       Impact factor: 9.754

3.  An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.

Authors:  Keith C Meyer; Ganesh Raghu; Robert P Baughman; Kevin K Brown; Ulrich Costabel; Roland M du Bois; Marjolein Drent; Patricia L Haslam; Dong Soon Kim; Sonoko Nagai; Paola Rottoli; Cesare Saltini; Moisés Selman; Charlie Strange; Brent Wood
Journal:  Am J Respir Crit Care Med       Date:  2012-05-01       Impact factor: 21.405

Review 4.  Clinical heterogeneity and outcomes of antisynthetase syndrome.

Authors:  Baptiste Hervier; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

Review 5.  Morbidity and mortality in adult polymyositis and dermatomyositis.

Authors:  Isabelle Marie
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

6.  Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients.

Authors:  Rohit Aggarwal; Elaine Cassidy; Noreen Fertig; Diane Carol Koontz; Mary Lucas; Dana P Ascherman; Chester V Oddis
Journal:  Ann Rheum Dis       Date:  2013-02-19       Impact factor: 19.103

7.  Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies.

Authors:  Johan Rönnelid; Sevim Barbasso Helmers; Helena Storfors; Katarina Grip; Lars Rönnblom; Karin Franck-Larsson; Gunnel Nordmark; Ingrid E Lundberg
Journal:  Autoimmun Rev       Date:  2009-03-11       Impact factor: 9.754

8.  Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid of individuals infected with human T-lymphotropic virus type 1.

Authors:  Noriho Sakamoto; Hiroshi Mukae; Takeshi Fujii; Tomoyuki Kakugawa; Hideyuki Kaida; Jun-Ichi Kadota; Shigeru Kohno
Journal:  Respir Med       Date:  2004-03       Impact factor: 3.415

9.  Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; E Hachulla; O Vittecoq; J-F Menard; F Jouen; S Dominique
Journal:  Eur J Intern Med       Date:  2013-02-01       Impact factor: 4.487

10.  Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.

Authors:  I Tillie-Leblond; M Wislez; D Valeyre; B Crestani; A Rabbat; D Israel-Biet; M Humbert; L J Couderc; B Wallaert; J Cadranel
Journal:  Thorax       Date:  2007-06-08       Impact factor: 9.139

View more
  9 in total

1.  Clinical characteristics of idiopathic interstitial pneumonias with anti-Ro52/tripartite motif-containing 21 antibodies.

Authors:  Masahiro Tahara; Noriho Sakamoto; Minoru Satoh; Hiroshi Ishimoto; Hirokazu Yura; Kei Yamasaki; Takashi Kido; Yoshihisa Fujino; Tomoko Hasegawa; Shin Tanaka; Kazuhiro Yatera; Hiroshi Mukae
Journal:  Sci Rep       Date:  2022-07-01       Impact factor: 4.996

Review 2.  Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond.

Authors:  Angeles S Galindo-Feria; Antonella Notarnicola; Ingrid E Lundberg; Begum Horuluoglu
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

3.  Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review.

Authors:  Tracy J Doyle; Namrata Dhillon; Rachna Madan; Fernanda Cabral; Elaine A Fletcher; Diane C Koontz; Rohit Aggarwal; Juan C Osorio; Ivan O Rosas; Chester V Oddis; Paul F Dellaripa
Journal:  J Rheumatol       Date:  2018-04-01       Impact factor: 4.666

Review 4.  Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.

Authors:  Christopher A Mecoli; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 5.  The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases.

Authors:  Caroline V Cotton; Lisa G Spencer; Robert P New; Robert G Cooper
Journal:  Rheumatology (Oxford)       Date:  2017-08-01       Impact factor: 7.580

Review 6.  Idiopathic Inflammatory Myopathies: A Review of the Classification and Impact of Pathogenesis.

Authors:  Dana E Mandel; Charles J Malemud; Ali D Askari
Journal:  Int J Mol Sci       Date:  2017-05-18       Impact factor: 5.923

7.  Acute Respiratory Failure as the First Manifestation of Antisynthetase Syndrome.

Authors:  Sonia Toujani; Amani Ben Mansour; Meriem Mjid; Abir Hedhli; Jouda Cherif; Yassine Ouahchy; Majed Beji
Journal:  Tanaffos       Date:  2017

8.  Antisynthetase syndrome: An under-recognized cause of interstitial lung disease.

Authors:  Venkata Nagarjuna Maturu; Arjun Lakshman; Amanjit Bal; Varun Dhir; Aman Sharma; Mandeep Garg; Biman Saikia; Ritesh Agarwal
Journal:  Lung India       Date:  2016 Jan-Feb

9.  PL-7 Antisynthetase Syndrome in Association with Sjögren's, Systemic Lupus Erythematosus, and Rheumatoid Arthritis.

Authors:  Mehrin Jawaid; Yael Ross; Mohammad Kamran
Journal:  Case Rep Rheumatol       Date:  2020-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.